Volume 38, Issue 5 pp. 399-403
Main Text Article

Effective Use of Alteplase for Occluded Tunneled Venous Catheter in Hemodialysis Patients

Marcela L. Mendes

Marcela L. Mendes

Internal Medicine, University of São Paulo State—Botucatu School of Medicine—UNESP, Botucatu, São Paulo, Brazil

Search for more papers by this author
João H. Castro

João H. Castro

Internal Medicine, University of São Paulo State—Botucatu School of Medicine—UNESP, Botucatu, São Paulo, Brazil

Search for more papers by this author
Tricya N. Silva

Tricya N. Silva

Internal Medicine, University of São Paulo State—Botucatu School of Medicine—UNESP, Botucatu, São Paulo, Brazil

Search for more papers by this author
Pasqual Barretti

Pasqual Barretti

Internal Medicine, University of São Paulo State—Botucatu School of Medicine—UNESP, Botucatu, São Paulo, Brazil

Search for more papers by this author
Daniela Ponce

Corresponding Author

Daniela Ponce

Internal Medicine, University of São Paulo State—Botucatu School of Medicine—UNESP, Botucatu, São Paulo, Brazil

Address correspondence and reprint requests to Prof. Daniela Ponce, University of São Paulo State—Botucatu School of Medicine—UNESP—Internal Medicine, Distrito de Rubiao Junior, Botucatu, São Paulo 18600000, Brazil. E-mail: [email protected]Search for more papers by this author
First published: 03 October 2013
Citations: 12

Abstract

Despite their propensity for significant infectious and mechanical complications, tunneled central venous catheters (CVCs) have become a common means of vascular access in the world for patients requiring chronic hemodialysis for end-stage renal disease. The objective of this study was to explore if cryopreserved solutions of the thrombolytic agent alteplase could be used as an effective, safe, and economically reasonable alternative in hemodialysis patients with occluded tunneled CVC. Patients requiring chronic hemodialysis and presenting with occluded tunneled CVC received a sufficient volume of the alteplase solution to fill the occluded catheter. To make alteplase economically feasible, it was diluted to 1-mg/mL aliquots and they were stored at −20°C until use. Eighty-one patients accounting for 179 attempted clearances were assessable for efficacy. One hundred forty-seven (82.1%) of the 179 catheter clearance attempts resulted in successful catheter clearance after one dose. Twenty-seven (15.1%) of all occluded CVCs were successful after two doses whereas five (2.8%) were not. No adverse events were reported. Cryopreserved 1-mg/mL aliquots of alteplase are safe and effective in the clearance of occluded CVC for hemodialysis patients.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.